GoldenGolden
BioNTech

BioNTech

BioNTech is a German company that develops immunotherapies for the treatment of cancer and other diseases.

Contents
Approach
PipelineCOVID-19
Timeline
Funding rounds
Products
People
Further reading
Documentaries, videos and podcasts
Companies
News
References

Primarily focused on developing individualized cancer therapy, BioNTech is a biotechnology company located in Mainz, Germany.

Approach

Their method revolves around several platforms in medicine; mRNA Therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators. Coupled with their approach to patient specific needs, they have seen success in providing unique treatments.

  1. Sequencing patient's tumor
  2. Mapping of mutations
  3. Bioinformatic algorithms
  4. Selection of neoepitopes

Pipeline

COVID-19

BNT162 is BioNTech’s mRNA vaccine program aimed at preventing COVID-19 infection. It is the first product candidate from Project Lightspeed and leverages BioNTech’s proprietary mRNA platforms for infectious diseases, its fully-owned GMP manufacturing infrastructure for mRNA vaccine production, and its global clinical development capabilities, drawing on BioNTech’s network of global collaborators. BioNTech is partnered with Pfizer for co-development and distribution of BNT162 and with Fosun Pharma on the vaccine development in China.

Timeline

November 25, 2020

BioNTech and Shanghai Fosun Pharmaceutical says they will launch a Phase II clinical trial of BioNTech's experimental COVID-19 vaccine in China.

November 12, 2020

Commission approves contract with BioNTech-Pfizer alliance to ensure access to a potential vaccine

The European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
‌
BioNTech funding round, January 2018
270,000,000
January 2018
Redmile Group
Janus Henderson Investors
Invus
Fidelity Investments
‌
BioNTech Series B round, July 2019
Series B round
325,000,000
July 9, 2019
Fidelity Management & Research Company
‌
BioNTech Funding Round 2018
91,500,000
January 4, 2018
‌
BioNTech funding round, January 2019
January 2019
Sanofi
4 Results
Results per page:
Page 1 of 1
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Özlem Türeci

Chief Medical Officer

Ryan Richardson

Chief Strategy Officer

Sean Marett

Chief Business and Chief Commercial Officer

Sierk Poetting

Chief Financial Officer and Chief Operating Officer

Ugur Sahin

Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

BioNTech Corporate Video

https://youtu.be/-7QOo7LXsp0

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Everything you need to know about the Pfizer/BioNTech covid-19 vaccine
Graham Lawton
December 3, 2020
New Scientist
A coronavirus vaccine made by Pfizer and BioNTech has received emergency authorisation in the UK and will begin to be available to the public soon
Britain OKs Pfizer vaccine and will begin shots within days
LAURAN NEERGAARD and DANICA KIRKA Associated Press
December 2, 2020
ABC News
Britain has become the first country in the world to authorize a rigorously tested COVID-19 vaccine and could be dispensing shots within days
Covid-19 news: UK care homes may get authorised Pfizer vaccine first
Michael Le Page, Clare Wilson, Jessica Hamzelou, Sam Wong, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool
December 2, 2020
New Scientist
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
Vaccine 1st puts spotlight on German pharma company BioNTech
By DAVID McHUGH and FRANK JORDANS
December 2, 2020
AP NEWS
MAINZ, Germany (AP) -- The email that arrived in the ancient German city of Mainz shortly before 1 a.m. in the morning marked a turning point in the global effort to deliver a reliable vaccine...
Wall Street slips from record levels as monthly private payrolls disappoint
Reuters
December 2, 2020
@bsindia
(Reuters) - Wall Street fell on Wednesday, with the S&P 500 and the Nasdaq retreating from the record levels hit in the previous session as fewer-than-expected private job additions in November added to concerns about the near-term pressure on the economy.
UK authorizes Pfizer coronavirus vaccine for emergency use
By LAURAN NEERGAARD and DANICA KIRKA
December 2, 2020
AP NEWS
British officials authorized a COVID-19 vaccine for emergency use on Wednesday, greenlighting the world's first shot against the virus that's backed by rigorous science and taking a major step...
In historic first, UK to introduce Pfizer-BioNTech vaccine next week
December 2, 2020
International Business Times UK
According to the World Health Organization, around 100 vaccine candidates are currently in development.
Stock market today: UK approves Pfizer and BioNTech's COVID-19 vaccine - Business Insider
Shalini Nagarajan
December 2, 2020
Business Insider
Approval of a highly effective vaccine may mark the beginning of a new bull market for equities, a global market strategist said.
Coronavirus vaccine update: Pfizer vaccine shots in UK from next week
BS Web Team
December 2, 2020
@bsindia
UK has become the first country to approve Pfizer coronavirus vaccine for rollout. Russia, India, Oxford vaccine are also making some progress. Catch latest coronavirus vaccine updates here
Covid-19 news: Pfizer/BioNTech vaccine authorised for use in the UK
Michael Le Page, Clare Wilson, Jessica Hamzelou, Sam Wong, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool
December 1, 2020
New Scientist
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
UK approves Pfizer and BioNTech COVID-19 vaccine, first in West - Business Insider
Dr. Catherine Schuster-Bruce
December 2, 2020
Business Insider
UK regulator, the Medicines and Healthcare products Regulatory Authority (MHRA) said Pfizer and BioNTech's vaccine's safe and works against COVID-19.
S&P 500, Nasdaq Composite hit record highs on vaccine, recovery hopes - Business Insider
Ben Winck
December 1, 2020
Business Insider
Cyclical sectors and value stocks continued to gain as investor cash moved further out of growth picks and into riskier plays.
Covid-19 news: European regulator delays assessment of vaccines
Michael Le Page, Clare Wilson, Jessica Hamzelou, Sam Wong, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool
December 1, 2020
New Scientist
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
S&P 500 climbs to record high as vaccine hopes lift economy-linked stocks
Ben Winck
December 1, 2020
markets.businessinsider.com
Investors cheered Pfizer and BioNTech's application for approval in the EU. The filing could allow for the shot to be distributed in December.
Pfizer and BioNTech seek EU clearance for COVID-19 vaccine - Business Insider
Kate Duffy
December 1, 2020
Business Insider
If EU regulators do not decide on Pfizer's COVID-19 vaccine until December 29, which is possible, rollout this year would be very difficult.
BioNTech's Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn
Hans-Werner Sinn
November 27, 2020
the Guardian
In close cooperation with the US pharmaceutical giant Pfizer, BioNTech's success augurs a rapid uptake of widespread vaccination in Europe and the US. Photograph: Anadolu Agency/Getty Images
BioNTech's Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn
Hans-Werner Sinn
November 27, 2020
the Guardian
In close cooperation with the US pharmaceutical giant Pfizer, BioNTech's success augurs a rapid uptake of widespread vaccination in Europe and the US. Photograph: Anadolu Agency/Getty Images
BioNTech, Fosun start COVID-19 vaccine trial to support Chinese approval
Nick Paul
November 25, 2020
FierceBiotech
BioNTech and Fosun Pharma have begun a phase 2 trial of their COVID-19 vaccine in China. The trial will generate data to support a filing for approval of the vaccine, which is nearing authorization in the West, in China.
BioNTech, Fosun start Phase II trial of Covid-19 vaccine in China
Reuters
November 25, 2020
@bsindia
BioNTech is also working with U.S. pharma giant Pfizer on the vaccine
Clinical Catch-Up: November 16-20
Mark Terry
November 23, 2020
BioSpace
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here's a look.
SHOW MORE

References

biontech.de
Is a
Company

Company attributes

Industry
Biotechnology
Medicine
RNA
Vaccine
Research and development
Drug discovery
Cancer immunotherapy
...
Location
Germany
Mainz
Company status
Active
B2X
‌
B2C
CEO
‌
Ugur Sahin
Founder
‌
Christoph Huber
‌
Ugur Sahin
Crunchbase
crunchbase.com/organiz...ntech-ag
Full address
An der Goldgrube 12 55131 Mainz Germany
Investors
Invus
MIG Fonds
Jebsen Capital
Founded date
2008
Email address
info@biontech.de
Phone number
49 6131 9084-0
Fax number
49 6131 9084-390
Total funding amount (USD)
686,500,000
Latest funding round date
July 9, 2019
Competitors
Kernal Biologics
Business model
Commerce

Categories

Related Topics

Contributors

Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Product
FeaturesPricingEnterprise
Legal
Terms & ConditionsPrivacy Policy
Help
Help centerAPI DocumentationContact Us
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.